metastatic castration-resistant prostate cancer

With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
Flag link:
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
Flag link:
J&J claims first approval for PARP combo Akeega
J&J claims first approval for PARP combo Akeega
Pharmaphorum
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
Flag link:
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
metastatic castration-resistant prostate cancer
Flag link:
Why Janux Therapeutics Shares Rose 33.1% This Week
Why Janux Therapeutics Shares Rose 33.1% This Week
Motley Fool
Janux Therapeutics
oncology
JANX007
clinical trials
metastatic castration-resistant prostate cancer
Flag link:
Macrogenics takes another shot at a novel immune checkpoint
Macrogenics takes another shot at a novel immune checkpoint
EP Vantage
Macrogenics
MGC018
orlotamab
enoblituzumab
prostate cancer
metastatic castration-resistant prostate cancer
Flag link:
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
Flag link:
AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
BioSpace
AstraZeneca
Merck
clinical trials
Lynparza
metastatic castration-resistant prostate cancer
prostate cancer
Flag link:
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Motley Fool
Exelixis
prostate cancer
metastatic castration-resistant prostate cancer
cabozantinib
Cabometyx
Flag link:
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
BioSpace
Pfizer
Astellas
prostate cancer
metastatic castration-resistant prostate cancer
Xtandi
Flag link:
Treating resistant prostate cancer by depriving a key hormone of its 'co-pilot'
Treating resistant prostate cancer by depriving a key hormone of its 'co-pilot'
Fierce Biotech
prostate cancer
metastatic castration-resistant prostate cancer
Carrick
C&7001
Flag link:
Marketing J&J eyes prostate cancer boost as FDA accepts Erleada for real-time review
Marketing J&J eyes prostate cancer boost as FDA accepts Erleada for real-time review
Fierce Pharma
JNJ
Erleada
FDA
prostate cancer
metastatic castration-resistant prostate cancer
Flag link:
New 'peptoids' show promise in resistant prostate cancer
New 'peptoids' show promise in resistant prostate cancer
Fierce Biotech
peptoids
metastatic castration-resistant prostate cancer
Flag link:
Clovis' Rubraca leads to 44% ORR in Phase II for CRPC
Clovis' Rubraca leads to 44% ORR in Phase II for CRPC
BioCentury
Clovis Oncology
Rubraca
rucaparib
metastatic castration-resistant prostate cancer
Flag link:
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
CP Wire
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer
Flag link:
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer
Flag link:
Tokai Pharmaceuticals stock plummets after drug trial discontinued
Tokai Pharmaceuticals stock plummets after drug trial discontinued
Marketwatch
Tokai
clinical trials
metastatic castration-resistant prostate cancer
prostate cancer
galeterone
Flag link:
Analyzing Medivation’s Growth Opportunity with Xtandi
Analyzing Medivation’s Growth Opportunity with Xtandi
Yahoo/Market Realist
Medivation
Xtandi
metastatic castration-resistant prostate cancer
prostate cancer
Flag link:
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Yahoo/Fly on the Wall
Exelixis
cabozantinib
metastatic castration-resistant prostate cancer
Flag link:
Teva rises on cancer updates
Teva rises on cancer updates
Globes, Israel
Teva
Lonquex
OncoGenex
Custiren
prostate cancer
metastatic castration-resistant prostate cancer
chemotheraphy-induced neutropenia
neutropenia
Flag link:

Pages